The Association Between Mutations in BRAF and Colorectal Cancer–Specific Survival Depends on Microsatellite Status and Tumor Stage

• Published in: Clinical gastroenterology and hepatology Vol. 17; no. 3; pp. 455 - 462.e6
• Main Authors: Bläker, Hendrik, Alwers, Elizabeth, Arnold, Alexander, Herpel, Esther, Tagscherer, Katrin E., Roth, Wilfried, Jansen, Lina, Walter, Viola, Kloor, Matthias, Chang-Claude, Jenny, Brenner, Hermann, Hoffmeister, Michael
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2019
• Subjects: Adult; Aged; Aged, 80 and over; Colon and Rectal Cancer; Colorectal Neoplasms - genetics; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Female; Genetic Predisposition to Disease; Genetics; Germany; Humans; Male; Microsatellite Repeats; Middle Aged; Mortality; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins B-raf - genetics; Retrospective Studies; Risk Assessment; Sequence Analysis, DNA; Survival Analysis; Germany; MSI; Prognosis; OS; DSS; Mortality; HR; MSS; CRC; FFPE; Colon and Rectal Cancer; Genetics; MSI-H; RFS
• ISSN: 1542-3565; 1542-7714
• DOI: 10.1016/j.cgh.2018.04.015

Colorectal tumors with mutations in BRAF and microsatellite stability (MSS) have been associated with adverse outcomes of patients. Combined tests for microsatellite instability-high (MSI-H) and BRAF mutations might therefore be used in risk assessment, particularly for patients with stage II tumors. We investigate the stage-specific prognostic value of combined testing for MSI-H and BRAF for patients with colorectal cancer. We performed a retrospective analysis of colorectal tumor samples collected from 1995 patients at 22 hospitals in Germany, between 2003 and 2010. Samples were analyzed for MSI-H using an established mononucleotide marker panel; BRAF mutations (BRAFV600E) were detected by Sanger sequencing or in tissue microarray blocks using immunohistochemistry. Cancers were assigned to categories of having MSS without mutations in BRAF, MSS with mutant BRAF, MSI-H without mutations in BRAF, and MSI-H with mutant BRAF. We investigated the association between tumor categories with clinical and pathologic features and patient’s overall, disease-specific, and recurrence-free survival (median follow-up time, 5.1 y). Tumors were stage I in 364 (18%), stage II in 678 (34%), stage III in 673 (34%), and stage IV (14%) in 280 patients. Sixty-three percent of tumors were located in the colon and 37% in the rectum. Most tumors (85%) had MSS without mutations in BRAF, 3% had MSS with mutant BRAF, 7% had MSI-H without mutations in BRAF, and 5% had MSI-H with mutant BRAF. In patients whose tumors were MSI-H, mutation of BRAF did not significantly affect survival time. Patients whose tumors had MSS with mutant BRAF had significantly reduced overall survival (hazard ratio [HR], 2.16; 95% CI, 1.54–3.04; P < .001), disease-specific survival (HR, 2.59; 95% CI, 1.77–3.79; P < .001), and recurrence-free survival (HR, 2.45; 95% CI, 1.70–3.52; P < .001) than patients whose tumors had MSS without BRAF mutation. Although BRAF mutations in tumors with MSS were associated with disease-specific survival of patients with stage III or IV tumors (P < .001), these features did not affect survival of patients with stage II tumors (P = .639). In an analysis of almost 2000 patients with colorectal cancer, we found BRAF mutations to reduce survival of patients in stage III or IV (but not stage II) tumors with MSS. These findings do not support testing stage I or II colorectal tumors for BRAF mutations, although additional large studies are needed.